Back to Search Start Over

O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies

Authors :
Bruno Permanne
Astrid Sand
Solenne Ousson
Maud Nény
Jennifer Hantson
Ryan Schubert
Christoph Wiessner
Anna Quattropani
Dirk Beher
Source :
ACS chemical neuroscience. 13(8)
Publication Year :
2022

Abstract

Neurodegenerative proteinopathies are characterized by the intracellular formation of insoluble and toxic protein aggregates in the brain that are closely linked to disease progression. In Alzheimer's disease and in rare tauopathies, aggregation of the microtubule-associated tau protein leads to the formation of neurofibrillary tangles (NFT). In Parkinson's disease (PD) and other α-synucleinopathies, intracellular Lewy bodies containing aggregates of α-synuclein constitute the pathological hallmark. Inhibition of the glycoside hydrolase O-GlcNAcase (OGA) prevents the removal of O-linked

Details

ISSN :
19487193
Volume :
13
Issue :
8
Database :
OpenAIRE
Journal :
ACS chemical neuroscience
Accession number :
edsair.doi.dedup.....75477687aadf539b6e3aa5f5e25f1137